Abstract: The invention discloses a method for the separation and purification of epothilones, especially discloses a method for the separation and purification of epothilones B and A using normal phase silica gel chromatography, which comprises loading the sample after dissolving the sample containing epothilones B and A with C1-C7 alkyl halide compounds or mixing the sample with silica gel, then gradient eluting silica gel column by an elution solvent of normal phase silica gel column, and finally obtaining products.

Abstract: The present invention provides N-methylethylcarbamino-3-[(S)-1-(methyl-[(S)-1-phenylethyl]amino)ethyl]phenyl ester represented by formula (II) and its preparation method. The present invention also provides (S)-1-(3-methoxyphenyl)-N-methyl-N—[(S)-1-phenylethyl]ethylamine and 3-[(S)-1-(methyl-[(S)-1-phenylethyl]amino)ethyl]phenol as intermediates of the compound represented by formula (II), and the use of the compound represented by formula (II) for preparing rivastigmine used for treating Alzheimer disease.

Abstract: An improved electrode useful for modifying a substrate using corona discharge dielectric barrier discharge or glow discharge plasma treatment or coating a substrate using plasma enhanced chemical vapor deposition under atmospheric or near atmospheric pressure conditions, the electrode having a body defining a cavity therein, the body having at least one inlet passageway there through in gaseous communication with the cavity so that a gas mixture can be flowed into the cavity by way of the at least one inlet passageway, the electrode having at least one outlet passageway there through in gaseous communication with the cavity so that a gas that is flowed into the cavity can flow out of the cavity by way of the at least one outlet passageway, the at least one outlet passageway being a slot.

Abstract: Use of ginsenoside Compound-K, which structural formula is the following: in manufacturing medicaments for prevention or treatment of arthritis.

Abstract: Processes for producing a suitable purity grade of L-Citrulline are disclosed. The processes can include contacting crude L-Citrulline in an aqueous solution with an adsorptive medium at a temperature above approximately 50° C. and below the temperature of denaturement for the L-Citrulline for an interval sufficient to remove at least one contaminant from the L-Citrulline. The processes can also include concentrating the dissolved L-Citrulline relative to the aqueous solution.

Abstract: An apparatus and a method for mixing at least two fluid substances and carrying out or initiating a reaction between them, wherein the apparatus is a static mixer are described. The static mixer includes a fluid receiving chamber, a first conduit passing through the fluid receiving chamber and having at least one tapered aperture therethrough, and a second conduit operatively connected to the fluid receiving chamber.

Abstract: The present invention provides a method for in vitro detection of malignant potential of dysplasia by aberrant methylation of p16 CpG islands, comprising extraction of genomic DNA from a tissue or body fluid sample, analysis of methylation status of p16 CpG islands in the extracted DNA, and evaluation of malignant potential of the tested tissue. The present invention also provides DNA compositions having artificial sequences of p16 CpG islands with or without methylation.

Abstract: The present invention is directed to a system for providing electrical power onboard a vehicle. In one embodiment, the system comprises: an AC/DC converter; an onboard power supply connected to the AC/DC converter so as to provide an input to the AC/DC converter; an external power source; a cable connected at one end to the external power source and at the other end to the AC/DC converter so as to provide electrical power from the external power source as an input to the AC/DC converter; and a controller, connected to the AC/DC converter and controlling various parameters of the selected power supply.

Abstract: Disclosed is a method for detecting a target antigen in a fluid sample of an individual. In preferred embodiments, the fluid sample is urine, cerebral spinal fluid, or synovial fluid. After an optional concentration step, the fluid sample is passed through a membrane suitable for binding the target antigen, thereby binding the target antigen to the membrane. Target antigen, bound to the membrane, is then detected using an antibody specific to the target antigen.